Compare General Motors Company (GM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Natera Inc. Common Stock — how do they compare? General Motors Company trades at $83.71 (market cap $73.71B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: General Motors Company is the larger of the two by market cap, and General Motors Company pays a 0.86% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Natera Inc. Common Stock for 0 Days on average.
| GM | NTRA | |
|---|---|---|
Market Cap | $73.71B | $57.03B |
Volume | 6,224,747 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $425.64 |
52-Week Low | $57.34 | $179.42 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $56.18B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $84.00, up 1.98% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue declined slightly in 2025. Analyst consensus is strongly positive with a $102.33 price target, but recent news highlights competitive pressures and a 5.5% drop in Q3 2026 U.S. vehicle sales.
GM faces headwinds from declining market share and weak electric vehicle demand, but cost savings from eased fuel economy rules and consistent earnings beats provide upside potential. Key risks include high debt levels and intense competition. The stock appears fundamentally undervalued on P/S and P/B metrics relative to analyst targets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
